DECOY THERAPEUTICS · BIOTECH
Naming a new category of antiviral, and telling its story everywhere.
The challenge
Decoy Therapeutics engaged TMC Studio when its preclinical antiviral platform didn’t fit any existing category. The Nasdaq-listed company needed one story that investors, partners and press would remember.
The approach
Find what’s truly different. Pinned down what set the science apart: one drug designed to work across many viruses.
Name it. Led a two-day positioning workshop with the leadership team that turned it into a category: Designable Multi-Antivirals, or D-MAVs.
Codify it. Wrote the brand communications guidebook: positioning, three messaging pillars and voice.
Tell it everywhere. Carried the story into the 10-K, investor deck, business development materials, press releases and award submissions, and brought in the right partner to build a new website around it.
The results
A new category. D-MAVs became one clear message, used consistently from the 10-K to the investor deck.
The website. The positioning carried all the way through to the company website.
Recognition. Winner, 2026 BioTech Breakthrough Award for R&D Solution of the Year. Finalist, Fierce AI Innovation Awards.
“Deck looks terrific. It sets a very professional and polished tone.”
Rick Pierce, CEO, Decoy Therapeutics